- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01141101
Risk Factors for Early Infant Colonization With Methicillin-Resistant Staphylococcus Aureus
The prevalence of Methicillin-resistant Staphylococcus aureus (MRSA) colonization and infections have been increasing in the general population, including the pediatric population. It has been reported that MRSA colonization persists for up to four years, and therefore the youngest pediatric patients, specifically those who are less than 2 years of age, have a high risk of prolonged colonization during a period of time when they are susceptible to significant skin and soft tissue infections (SSTIs) attributable to MRSA. Once prolonged colonization takes place, recurrent SSTIs are commonplace, resulting in substantial morbidity and in some cases mortality, as well as a significant cost to the healthcare system. Individuals colonized with MRSA have an increased risk of developing MRSA infections, which range from mild disease, such as carbuncles, to severe infections, such as necrotizing pneumonia and toxic shock syndrome. The prevalence of severe MRSA infections is also greatest in neonates and infants, where increased MRSA colonization has been observed. In the early infant period, the most common manifestation of MRSA disease is pustular skin lesions, which affect approximately 5% of the general population, with MRSA-colonization being a major risk factor for this disease. Moreover, the prevalence of pustular disease is increasing in the general population, and there are numerous case reports of invasive, life-threatening MRSA disease in the early infant period.
Corresponding to the increasing prevalence in the community, the carriage of MRSA in pregnant women has also escalated, and vaginal carriage is significant in pregnant women. As an analogy, maternal vaginal Group B Streptococcal (GBS) colonization is the major risk for infant colonization regardless of whether early or late neonatal colonization or disease occurs. It is quite feasible that vaginal MRSA carriage predisposes newborns to colonization during the birthing process; however, this mechanism has not yet been well studied. There are other mechanisms implicated for early infant colonization, including close contact with MRSA-colonized mothers through daily care and breastfeeding. MRSA colonization in one household member greatly predisposes colonization in others; therefore, early infant colonization could result from contact with other MRSA-colonized individuals in a household. Currently, it is not clear which factors are the most important in influencing early infant MRSA colonization and subsequent infection.
Not only is the prevalence of MRSA colonization and infection on the rise, but there have been few if any measures that have been established to prevent colonization and subsequent infection in adults and children. Eradication measures have shown limited long-term benefit. If vertical transmission of MRSA can be established as a critical event in the pathogenesis of disease, potentially effective strategies could be tested, and possibly the spread of MRSA in the community interrupted.
Hypotheses and Specific Aims:
- Identify the proportion, rate and time of MRSA colonization in infants born to mothers with and without MRSA colonization;
- Compare risk factors for infant MRSA colonization in these two groups;
- Determine the prevalence and risk factors for developing MRSA infections in the MRSA-colonized infant.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02118
- Boston Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
The exposed group will include 100 MRSA-colonized mothers and their babies. The unexposed group will include 100 MRSA-negative mothers and their babies. The groups will be conveniently selected from all mothers and infants meeting the inclusion and exclusion criteria each month. Enrollment will continue until 100 babies and mothers in the MRSA-positive mother group and 100 babies and mothers in MRSA-negative mother group are enrolled. We estimate that enrollment will require approximately 18 months to complete.
Household contacts of infants will be enrolled. A contact is defined as any individual who had or has had the same primary residences (who has lived in the same house for at least one week) as the infant since the infant's birth. We will ask the infants mother to identify the infants household contacts.
Infant care givers include any person who provides daily care to infant for at least 4 hours per day at least 3 days of week.
Description
Inclusion Criteria:
- Infants born at > 32 weeks of gestation.
- Mother must have been tested for MRSA prior to birth.
- Mother must be willing to provide informed consent for herself and infant.
- Mothers feel household contacts and caregivers will be willing to enroll in the study.
- Household contacts must be willing to provide informed consent (if greater than 18 years of age) or parent of household contact must be willing to provide informed consent for minors and the minor must provide assent (if greater than age 7) to enroll in study.
- Infant care givers must be willing to provide informed consent (if greater than 18 years of age) or parent of infant care giver must be willing to provide informed consent for minors and the minor must provide assent (if greater than age 7) to enroll in study.
Exclusion criteria:
- Infants born at < 32 weeks gestation.
- Infants who will not be receiving their primary care at Boston Medical Center.
- Household contact or Infant Care giver not willing to provide informed consent.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
MRSA-exposed
The MRSA-exposed group will include 100 MRSA-colonized mothers and their babies
|
MRSA-unexposed
The MRSA-unexposed group will include 100 MRSA-negative mothers and their babies.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
We will compare infants' MRSA-positivity rates in the exposed versus the unexposed study groups.
Time Frame: 18 months
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
We will determine if infant MRSA positivity appears earlier in exposed infants versus unexposed infants.
Time Frame: 18 months
|
18 months
|
For infants who become MRSA-positive we will determine if their strain of MRSA is the same as their mothers' or other household contacts or care giver who is determined to be MRSA-positive.
Time Frame: 18 months
|
18 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-29160
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Methicillin-resistant Staphylococcus Aureus
-
University of Colorado, DenverAmerican Academy of Family Physicians National Research NetworkCompletedMethicillin-Resistant Staphylococcus AureusUnited States
-
University Hospital, ToulouseCompletedMethicillin-Resistant Staphylococcus AureuS
-
University of Sao PauloUnknownMethicillin Resistant Staphylococcus AureusBrazil
-
University of FloridaRecruitingMethicillin-Resistant Staphylococcus AureusUnited States
-
Assistance Publique - Hôpitaux de ParisTerminatedMethicillin-Resistant Staphylococcus AureusFrance
-
University of Lausanne HospitalsCompletedMethicillin-Resistant Staphylococcus Aureus
-
NorthShore University HealthSystemAgency for Healthcare Research and Quality (AHRQ)CompletedMethicillin Resistant Staphylococcus AureusUnited States
-
University of California, IrvineAgency for Healthcare Research and Quality (AHRQ)CompletedMethicillin-Resistant Staphylococcus AureusUnited States
-
Pinyo RattanaumpawanUnknownMethicillin-Resistant Staphylococcus AureusThailand
-
Mercy ResearchWithdrawnMethicillin-Resistant Staphylococcus Aureus